Women with early-stage breast cancer
in one breast are increasingly opting to undergo a more aggressive
operation to remove both breasts called contralateral prophylactic
mastectomy (CPM). Rates of double mastectomies have more than doubled
over the last decade for women with early-stage cancer,
but for women with cancer in one breast, having the healthy breast
removed may not provide a survival benefit, according to new research
findings presented at the 2013 Clinical Congress of the American College
of Surgeons.
According to the American Cancer Society, more than 232,000 women are
diagnosed with breast cancer in the U.S. every year,* making breast
cancer the second most common type of cancer in women, after skin cancer.
Many women who face this diagnosis worry about cancer recurring in the
healthy breast and therefore choose to have both breasts removed, even
though the risk of developing cancer in the other breast is very low.
Women at high risk include those with a family history of breast or ovarian cancer and women who test positive for the BRCA1 and BRCA2 gene mutations.
Importantly, until now no study has looked at the decision-making
processes that lead women to choose CPM. "There have been several
studies in the last couple of years indicating that there may be a
survival benefit for selected patients by having their healthy breast
removed," said study coauthor Todd M. Tuttle, MD, FACS, chief of
surgical oncology, University of Minnesota, Minneapolis. "This research
will provide physicians and patients with accurate and easily understood
information about whether removal of the healthy breast will impact
their survival at all."
To better understand the effect of CPM on life expectancy, the
researchers conducted an analytic modeling study among women without a
BRCA gene mutation. Within this group, the researchers compared women
who underwent CPM with women who did have early-stage breast cancer in
one breast and no prophylactic operation to remove the second breast.
The study authors primarily analyzed data from the Early Breast Cancer
Trialists' Collaborative Group (EBCTCG) and the Surveillance,
Epidemiology, and End Results (SEER) program to determine the risk of
developing contralateral breast cancer (CBC), dying from CBC, dying from
primary breast cancer, and the reduction in CBC due to CPM. The two
databases include information on the treatment and survival of early
breast cancer and include more than 100,000 women who have participated
in randomized trials over the last 30 years across the United States.
For the study, the researchers estimated the life expectancy gain of CPM
among sub-groups of women newly diagnosed with cancer in one breast by
age 40 to 60 years, estrogen receptor status as positive or negative,
and stage of cancer I or II. They found that the maxi- mum life
expectancy gain for women who underwent CPM was six months for all
scenarios including age, estrogen receptor status, and cancer stage
groups.
Because many women are driven by their fears of contracting a second
cancer in their healthy breast, they choose a double mastectomy, the
more aggressive treatment. This procedure is a bigger operation
associated with a longer recovery period and potentially more
complications. Thus, experts are concerned that some patients are being
overtreated with a prophylactic procedure.
"I think this decision model study will provide women who are
considering these extensive operations with more accurate information
about whether or not CPM is going to improve their survival," Dr. Tuttle
said. With this analytic modeling tool, women and physicians can make
more informed and better decisions when choosing between different
treatments. These results can help educate women that a contralateral
mastectomy will not improve their survival rate if they don't have
hereditary breast cancer, he explained.
"This information may ultimately help them answer an important question:
'If I have that opposite breast removed, is that procedure really going
to improve the likelihood that I will be alive 10 to 20 years from
now?'"
No comments:
Post a Comment